An interventional study of active nVNS and Sham in Insomnia, Major Depressive Diorder and miRNAs, sponsored by University of Alabama at Birmingham. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 905 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 148 open to participants now, 185 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.
Among the 905 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 535th largest by planned enrollment of the 857 interventional ones that give a count, is one of 61 that started in 2026, is one of 579 with no phase, reaches primary completion later than 150 of the 184 other live ones, and was the 903rd registered.
2,730 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →148 of the 905 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
Florida State University · Sites in United States
Ages 6–13 · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+ · Women only
Eight Sleep Inc. · Sites in United States
Ages 45+ · Healthy volunteers
Proactive Life Inc · Sites in United States
Ages 55+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
905 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 103 · Phase 3 77 · Phase 4 78
First in 1997; this study’s year is marked. 61 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 68 across 2,357 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 60 across the 857 interventional studies, 72 across the 48 observational. Of the 660 that completed or were terminated, 243 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 905 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 278 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 4 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
79 of the studies in Sleep Initiation and Maintenance Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06655883Phase 3Merck Sharp & Dohme LLCA Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | 2027-06-24 |
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
| NCT06953869Phase 3Vanda PharmaceuticalsEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | 2027-11 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 79 to your calendar (.ics) → With an account.
Among the 905 studies in Sleep Initiation and Maintenance Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material.
The main questions it aims to answer are:
This study lasts about 7 weeks.
Participants will be asked to do the following:
Visit 1/ Baseline (in person):
This visit will last about 2 hours.
Weeks 1-6 (at home):
Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person):
This visit will last about 1.5 - 2 hours.
The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.
Major depressive disorder (MDD) and insomnia are highly prevalent, frequently co-occur, and rank among the leading causes of disability worldwide. Up to 80% of people with MDD report significant sleep disturbance, and persistent insomnia predicts higher relapse, poorer treatment response, and greater functional impairment. Autonomic dysregulation, commonly indexed by reduced heart rate variability (HRV), is a shared feature of both conditions and a marker of poor outcome [1], alongside circadian disruption and neuroinflammatory signaling.
Cervical transcutaneous vagus nerve stimulation (ctVNS) engages vagal afferents transcutaneously and may rebalance sympathetic-parasympathetic tone [2,3] and attenuate neuroinflammatory signaling implicated in anxiety and depression [4], with downstream effects on emotion-regulatory circuits and on sleep. Despite this mechanistic plausibility, treatment response to ctVNS remains heterogeneous and mechanistically unclear, and no validated marker identifies who will benefit.
Circulating microRNAs (miRNAs) are stable, accessible post-transcriptional regulators whose peripheral profiles are altered in MDD and may track with diagnosis or relapse risk [5,6]. Preclinical evidence shows that vagus nerve stimulation, which engages the same afferent pathways as ctVNS, modulates stress- and neuroplasticity-related miRNAs (for example, miR-183-3p) [7-9]. Neural-derived exosomes (NDE) isolated from plasma are enriched for signals of neuronal origin and provide a means of interrogating brain-relevant molecular processes from a peripheral blood sample.
Neuromodulation is changing how mental and other central nervous system disorders are treated, but its clinical use is limited by an inability to predict who will respond or why. Three specific gaps slow progress: (1) the pathways linking ctVNS to improvements in sleep and depression remain unclear; (2) no study has combined continuous wearable monitoring with circulating candidate biomarkers to predict response; and (3) the relationship between autonomic change and depression improvement has not been defined.
This study addresses those gaps by combining longitudinal wearable-derived autonomic monitoring, subjective and objective sleep phenotyping, standardized clinical outcomes, and circulating neural-derived exosomal miRNA profiling within a single mechanistic framework. The design separates sleep-mediated from sleep-independent autonomic pathways underlying changes in depression.
A within-subject sham run-in was selected rather than a parallel randomized design because the aim of this pilot is within-subject signal detection and effect-size estimation rather than controlled efficacy testing. The sham run-in establishes a stable, expectancy-adjusted personal baseline and prevents carryover from active stimulation from contaminating that reference. A fixed sham-to-active order partially confounds treatment with time; this limitation is stated explicitly, is mitigated by the end-of-sham anchor and by a group-level autonomic target-engagement check, and is addressed in the planned subsequent randomized, concurrent sham-controlled trial.
Healthy reference participants (Cohort B) are enrolled not as efficacy subjects but to establish normative ranges for HRV, sleep metrics, and candidate miRNA expression, enabling interpretation of disease-related biomarker deviations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible, participants must meet all of the following criteria:
Regular sleep opportunity of at least 6 hours per 24-hour period.
Cohort A (symptomatic) - additional inclusion criteria:
If receiving psychotropic medication or psychotherapy, the regimen has been stable for at least 6 weeks before Visit 1, and the participant and treating clinician agree it will remain stable through Visit 3.
Cohort B (healthy reference) - additional inclusion criteria:
Exclusion Criteria:
Participants meeting any of the following criteria are not eligible:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inactive sham stimulation, twice daily. Each participant receives first.
Device: Sham
Blinded active cervical nVNS, twice daily. Each participant receives second.
Device: active nVNS
ctVNS
sham run-in ctVNS
Primary physiologic endpoint as change in parasympathetic heart rate variability (nocturnal RMSSD).
Linear mixed-effects models estimating within-subject physiologic change from the end-of-sham anchor (week 2), with participant as a random effect and phase, time, cohort, age, sex, and body mass index as fixed effects.
Time frame: Change from Visit 2 (week 2) to Visit 3 (week 6).
Primary clinical endpoint as change in Insomnia Sleep Index (ISI) total score in Cohort A (affected).
The ISI is a 7-item self-report questionnaire used to assess nature, severity and impact of insomnia over previous 2 weeks. Each item is rated 0-4 , with total score range of 0-28. Higher score indicates greater insomnia severity. Response is defined as ≥ 50% reduction in ISI total score or remission (ISI ≤ 7).
Time frame: Change from Visit 2 (week 2) to Visit 3 (week 6).
Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score in Cohort A (affected) from Visit 2 to Visit 3.
The MADRS is a 10-item clinician rated scale used to assess severity of depression symptoms. Each item is scored from 0 to 6, with total possible score range of 0-60. A total score of 0-8 indicates no depression, and 8 or above would indicate some level of depression ranging from mild to severe. Higher score indicates greater depression symptoms.
Time frame: Change from Visit 2 (week 2) to Visit 3 (week 6).
Differential expression of neural-derived exosomal microRNAs from Visit 2 to Visit 3.
Differential expression screening with Benjamini-Hochberg false discovery rate control (q \< 0.05), followed by exploratory penalized regression classifiers with nested cross-validation and reporting of optimism-corrected performance.
Time frame: Change from Visit 2 (week 2) to Visit 3 (week 6).
Plan to share: No
Start is estimated for Dec 2026; primary completion for Sep 2028, 21 months later.
Of 1,213 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 21 months is above that.
Counting every sponsor, half of 1,291 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
University of Alabama at Birmingham →